相关实验视频

Updated: Sep 19, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

默克尔细胞癌:当前的治疗格局和新兴的治疗目标

Kelly Pan¹, A Maria Vromans¹, Liang Cheng²

¹Department of Internal Medicine, Brown University Health, Providence, RI, USA.

Current oncology reports

|June 3, 2025

概括

默克尔细胞癌 (MCC) 是一种侵袭性皮肤癌,往往是晚诊断的. 目前的治疗方法包括针对局部疾病进行手术,针对晚期疾病进行免疫治疗,正在开发新疗法.

科学领域:

在瘤学瘤学.
皮肤病学皮肤病学
免疫学免疫学免疫学

背景情况:

默克尔细胞癌 (MCC) 是一种罕见的,侵袭性的神经内分泌性皮肤癌.
它主要是由默克尔细胞多细胞病毒 (MCPyV) 和紫外线辐射引起的.
由于微妙的呈现,延迟诊断导致晚期检测和不良预后.

研究的目的:

审查MCC的诊断工作.
检查MCC中的预后标志物.
讨论当前和新兴的MCC治疗方法.

主要方法:

对诊断方法的文献审查.
对预后指标的分析.
综合当前的治疗方式.
评估正在进行的新疗法临床试验.

主要成果:

使用辅助辐射进行手术切除是当地MCC的标准.
PD-1/PD-L1抑制剂是高级或不可切除的MCC的标准治疗方法.
许多临床试验正在研究新型免疫疗法,向治疗和针对晚期或复发性MCC的疫苗.

结论:

MCC是一种具有迅速发展的治疗格局的侵袭性恶性瘤.
新兴疗法显示有希望改善先进MCC的治疗结果.
持续的研究对于改善患者预后至关重要.

关键词:

检查点抑制剂检查点抑制剂免疫治疗是一种免疫疗法.梅克尔细胞癌瘤是什么?默克尔细胞多细胞病毒 (MCPyV)在PD-1中使用PD-1.在PD-L1中.

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...